uniqure n.v. - QURE
QURE
Close Chg Chg %
52.65 1.66 3.15%
Closed Market
54.31
+1.66 (3.15%)
Volume: 11.30M
Last Updated:
Sep 26, 2025, 4:00 PM EDT
Company Overview: uniqure n.v. - QURE
QURE Key Data
| Open $51.05 | Day Range 49.20 - 55.11 |
| 52 Week Range 4.45 - 55.11 | Market Cap $2.89B |
| Shares Outstanding 54.87M | Public Float 49.01M |
| Beta 0.13 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.92 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.65M |
QURE Performance
| 1 Week | 291.56% | ||
| 1 Month | 232.58% | ||
| 3 Months | 291.85% | ||
| 1 Year | 969.09% | ||
| 5 Years | 45.41% |
QURE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
14
Full Ratings ➔
About uniqure n.v. - QURE
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
QURE At a Glance
uniQure NV
Paasheuvelweg 25a
Amsterdam, Noord-Holland 1105 BP
| Phone | 31-20-240-60-00 | Revenue | 27.12M | |
| Industry | Biotechnology | Net Income | -239,556,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 71.173% | |
| Fiscal Year-end | 12 / 2025 | Employees | 209 | |
| View SEC Filings |
QURE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 31.681 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.783 |
| Enterprise Value to Sales | 36.602 |
| Total Debt to Enterprise Value | 0.505 |
QURE Efficiency
| Revenue/Employee | 129,755.981 |
| Income Per Employee | -1,146,200.957 |
| Receivables Turnover | 4.611 |
| Total Asset Turnover | 0.039 |
QURE Liquidity
| Current Ratio | 9.744 |
| Quick Ratio | 9.744 |
| Cash Ratio | 9.176 |
QURE Profitability
| Gross Margin | -14.193 |
| Operating Margin | -679.501 |
| Pretax Margin | -874.394 |
| Net Margin | -883.351 |
| Return on Assets | -34.513 |
| Return on Equity | -238.461 |
| Return on Total Capital | -48.47 |
| Return on Invested Capital | -39.188 |
QURE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 101.366 |
| Total Debt to Total Assets | 90.02 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 100.638 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Uniqure N.v. - QURE
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 524.00M | 106.48M | 15.84M | 27.12M | |
Sales Growth
| +1,296.82% | -79.68% | -85.12% | +71.17% | |
Cost of Goods Sold (COGS) incl D&A
| 32.28M | 11.88M | 25.53M | 30.97M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 7.30M | 8.54M | 11.90M | 12.64M | |
Depreciation
| - | 8.14M | 11.80M | 10.14M | |
Amortization of Intangibles
| - | 400.00K | 100.00K | 2.50M | |
COGS Growth
| - | -63.19% | +114.88% | +21.31% | |
Gross Income
| 491.73M | 94.60M | (9.69M) | (3.85M) | |
Gross Income Growth
| - | -80.76% | -110.24% | +60.26% | |
Gross Profit Margin
| +93.84% | +88.84% | -61.13% | -14.19% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 185.86M | 237.03M | 261.66M | 180.43M | |
Research & Development
| 136.87M | 190.51M | 198.97M | 141.63M | |
Other SG&A
| 48.99M | 46.52M | 62.69M | 38.79M | |
SGA Growth
| +20.43% | +27.54% | +10.39% | -31.05% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 1.24M | 4.02M | 15.60M | 3.66M | |
EBIT after Unusual Expense
| 304.63M | (146.45M) | (286.94M) | (187.93M) | |
Non Operating Income/Expense
| 35.65M | 29.90M | 21.94M | 14.55M | |
Non-Operating Interest Income
| 162.00K | 609.00K | 19.56M | 21.42M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 7.47M | 11.70M | 41.56M | 63.74M | |
Interest Expense Growth
| +95.40% | +56.60% | +255.07% | +53.38% | |
Gross Interest Expense
| 7.47M | 11.70M | 41.56M | 63.74M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 332.81M | (128.26M) | (306.56M) | (237.13M) | |
Pretax Income Growth
| +335.29% | -138.54% | -139.01% | +22.65% | |
Pretax Margin
| +63.51% | -120.45% | -1,934.97% | -874.39% | |
Income Tax
| 3.22M | (1.47M) | 1.92M | 2.43M | |
Income Tax - Current - Domestic
| 7.00K | 24.00K | 110.00K | 145.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 3.21M | (1.49M) | 1.81M | 2.28M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 329.59M | (126.79M) | (308.48M) | (239.56M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 329.59M | (126.79M) | (308.48M) | (239.56M) | |
Net Income Growth
| +363.62% | -138.47% | -143.30% | +22.34% | |
Net Margin Growth
| +62.90% | -119.07% | -1,947.09% | -883.35% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 329.59M | (126.79M) | (308.48M) | (239.56M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 329.59M | (126.79M) | (308.48M) | (239.56M) | |
EPS (Basic)
| 7.1671 | -2.7129 | -6.471 | -4.9242 | |
EPS (Basic) Growth
| +354.90% | -137.85% | -138.53% | +23.90% | |
Basic Shares Outstanding
| 45.99M | 46.74M | 47.67M | 48.65M | |
EPS (Diluted)
| 7.0363 | -2.7129 | -6.471 | -4.9242 | |
EPS (Diluted) Growth
| +350.25% | -138.56% | -138.53% | +23.90% | |
Diluted Shares Outstanding
| 46.84M | 46.74M | 47.67M | 48.65M | |
EBITDA
| 313.17M | (133.89M) | (259.44M) | (171.63M) | |
EBITDA Growth
| +372.85% | -142.75% | -93.77% | +33.85% | |
EBITDA Margin
| +59.77% | -125.74% | -1,637.60% | -632.89% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 59.333 | |
| Number of Ratings | 14 | Current Quarters Estimate | -0.925 | |
| FY Report Date | 09 / 2025 | Current Year's Estimate | -3.264 | |
| Last Quarter’s Earnings | -0.69 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -4.92 | Next Fiscal Year Estimate | -3.139 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 13 | 13 | 13 | 13 |
| Mean Estimate | -0.92 | -0.78 | -3.26 | -3.14 |
| High Estimates | -0.63 | 0.52 | -1.91 | -1.71 |
| Low Estimate | -1.06 | -1.50 | -4.04 | -4.29 |
| Coefficient of Variance | -14.20 | -63.03 | -17.49 | -22.06 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 12 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Uniqure N.v. - QURE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Uniqure N.v. - QURE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 6, 2025 | Matthew C. Kapusta CEO, Managing Director; Director | 679,795 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Matthew C. Kapusta CEO, Managing Director; Director | 651,454 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.29 per share | 6,703,461.66 |
| Mar 6, 2025 | Matthew C. Kapusta CEO, Managing Director; Director | 171,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Walid Abi-Saab Chief Medical Officer | 153,253 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Walid Abi-Saab Chief Medical Officer | 151,903 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.29 per share | 1,563,081.87 |
| Mar 6, 2025 | Walid Abi-Saab Chief Medical Officer | 66,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Christian Klemt Chief Financial Officer | 228,168 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Christian Klemt Chief Financial Officer | 217,730 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.29 per share | 2,240,441.70 |
| Mar 6, 2025 | Christian Klemt Chief Financial Officer | 126,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Jeannette Potts Chief Legal Officer | 126,819 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Jeannette Potts Chief Legal Officer | 119,743 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.29 per share | 1,232,155.47 |
| Mar 6, 2025 | Jeannette Potts Chief Legal Officer | 60,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |